Latest news with #SilexionTherapeutics
Yahoo
30-05-2025
- Business
- Yahoo
Silexion Therapeutics announces preclinical results on SIL204
Silexion Therapeutics (SLXN) announced compelling preclinical data demonstrating the efficacy of its next-generation RNAi therapeutic candidate, SIL204, against human pancreatic, colorectal and lung, NSCLC, cancer cell lines. These results significantly expand SIL204's therapeutic potential beyond pancreatic cancer, allowing it to potentially address major KRAS-driven cancers with substantial unmet medical needs. Following the Company's recent announcement of completion of preclinical studies, a comprehensive analysis of the data has revealed that SIL204 effectively inhibited the proliferation and metabolic activity of human cancer cell lines harboring KRAS G12D mutations across multiple cancer types, resulting in the following obvervations: The data reveals SIL204 successfully inhibited the proliferation and metabolic activity of human cancer cell lines harboring a specific KRAS mutation: GP2D, A427 and Panc-1, in a statistically significant manner. The significant inhibition was observed in a dose-dependent manner down to nanomolar concentrations. As observed in the left hand graph below, a dose-dependent reduction in cell viability was noted in GP2D colorectal cancer cells, even in the absence of external additives, due to the lipid end of SIL204. Notably, as can be seen in the right hand graph below, the Company observed an inhibition rate of approximately 90% in the presence of SIL204 in GP2D colorectal cancer cells. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on SLXN: Disclaimer & DisclosureReport an Issue Silexion Therapeutics Receives Nasdaq Delisting Notice Silexion Completes Key Preclinical Studies for SIL204 Silexion Therapeutics completes preclinical studies on SIL204 Silexion Therapeutics' Promising Future: Buy Rating Backed by Expanding Market Potential and Strong Financial Position Silexion Therapeutics Partners with Catalent for SIL204 Development
Yahoo
22-05-2025
- Business
- Yahoo
PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment
New Report Covers Silexion Therapeutics, A Unique Precision Oncology Player New York, May 22, 2025 (GLOBE NEWSWIRE) -- PESG Research today announced the release of a report examining Silexion Therapeutics, an innovative biotechnology company developing unique RNA interference (RNAi) therapies targeting KRAS-driven cancers. The below report explores the company's disruptive technological approach, recent scientific milestones, and potential implications for cancer treatment strategies, in the fast growing precision oncology market. Executive Summary The precision oncology landscape is experiencing a potential breakthrough with Silexion Therapeutics' innovative approach to addressing KRAS-driven cancers. KRAS mutations represent one of the most challenging oncogenic drivers in cancer, historically resistant to traditional therapeutic interventions. Silexion's lead candidate, SIL204, represents a novel approach to cancer treatment, demonstrating promising preclinical results in reducing both primary tumor growth and metastatic spread across multiple cancer types, including pancreatic, colorectal, and lung cancers. The company's approach offers a fundamentally different strategy to cancer treatment, with potential to address some of the most aggressive and hard-to-treat malignancies. By targeting genetic mechanisms of cancer progression, Silexion is positioning itself at the forefront of precision oncology research. This report includes partner content. We advise readers to refer to the disclaimers and disclosures included at the end of this report. Technological Platform Silexion's core technology distinguishes itself by targeting KRAS mutations at the genetic level, a fundamentally different approach from traditional small molecule inhibitors. The RNA interference (RNAi) platform aims to prevent the production of oncogenic proteins, offering a potentially more comprehensive method of disrupting cancer cell proliferation. The SIL204 candidate demonstrates the ability to target multiple KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D. This broad targeting is critical given the prevalence of KRAS mutations in various cancer types: approximately 90% in pancreatic cancers, 45% in colorectal cancers, and 35% in non-squamous non-small-cell lung cancers. Preclinical Developments A significant milestone was achieved in March 2025 with the completion of orthotopic pancreatic cancer model studies. These studies utilized clinically relevant models where human tumor cells are implanted directly into the pancreas, providing a more accurate representation of cancer progression than traditional xenograft models. The research demonstrated notable efficacy across multiple cancer cell lines. In orthotopic models, SIL204 showed significant reductions in tumor cell numbers across different pancreatic cancer cell lines, with results varying by specific cell line and mutation profile. This approach offers a more nuanced understanding of potential therapeutic interventions. Strategic Approach Silexion has developed a sophisticated approach to drug delivery, focusing on two primary administration routes: systemic delivery for targeting metastatic progression and intratumoral delivery for primary tumor treatment. The company's collaboration with Catalent aims to optimize formulation development and clinical manufacturing processes, enhancing the potential efficacy of SIL204. The company's strategy extends beyond a single cancer type, with ongoing research exploring potential applications in colorectal and lung cancers. This broad approach reflects a comprehensive understanding of KRAS-driven malignancies and their complex biological mechanisms. The Road Ahead Silexion's development roadmap reportedly includes continued preclinical studies, planned toxicology and pharmacodynamic investigations, potential regulatory submissions, and anticipated initiation of human clinical trials in the first half of 2026. While the approach shows significant promise, it is crucial to recognize the challenges inherent in translating preclinical research into clinical treatments. The scientific community will be watching closely as Silexion continues to advance its innovative approach to cancer therapy. If succesfulm Silexion's contribution to the field of cancer therapeutics and precision oncology could be major. News Highlights from Silexion Therapeutics Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies >> Click here to Subscribe for more updates like this or go to & Disclosure: Nothing in this report constitutes medica, financial or professional advice. This report is published by PESG Research . The operators of PESG Research, a digital promotional content brand which is compensated to provide digestable and favorabel coverage of comapnies. This report contains and is a form of paid promotional content or advertisement for Silexion Therapeutics and was produced as part of the fee's they pay PESG's operators, Arx Advisory. This report has not been reviewed or approved by Silexion Therapeutics prior to publication. The operators of PESG Research received or are expected to receive a monthly recurring fee of five thousand united states dollars via wire transfer from Silexion Therapeutics as part of an ongoing agreement starting September 1, 2024 in return for social media distribution and promotional coverage services, and receive additional compensation for non promotional unrelated data and advisory services on top of that. Please review the full disclaimers and compensation disclosures here for further details: Readers are advised to refer to the official materials of the company aforementioned. The report should not be treated as objective. Contacts PESG Editorial Deskronald@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-01-2025
- Business
- Yahoo
PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market
Silexion Therapeutics reported 50% Tumor Reduction in Breakthrough Preclinical Systemic Administration Data; Maxim Group Analyst recently gave the company a Strong Buy Rating and a $9 Price Target as Company Advances RNAi Platform for KRAS-Driven Cancers Amid Hot Precision Oncology M&A Market and a series of Multi-Billion Dollar Acquisitions in the field NEW YORK, January 29, 2025--(BUSINESS WIRE)--PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN)* continues to strengthen its position in the precision oncology landscape with breakthrough preclinical data validating systemic administration of SIL-204, potentially opening new frontiers in treating KRAS-driven cancers. This development comes amid increasing industry appetite for innovative oncology assets, exemplified by recent multi-billion dollar acquisitions. Silexion's latest preclinical findings mark a significant advancement in RNAi therapeutics, with data showing 50% tumor growth reduction and complete necrosis in half of treated tumors after 30 days, sustained therapeutic levels for over 56 days from a single administration, and broad coverage of key KRAS mutations (G12D, G12V, G12R, Q61H, and G13D). These results build upon previous successes, including promising synergy with first-line chemotherapies and the strategic collaboration with Evonik for advanced PLGA microparticle formulation. The precision oncology landscape has witnessed unprecedented consolidation, with Pfizer's $43 billion acquisition of Seagen and AbbVie's $10.1 billion purchase of Immunogen exemplifying the industry's willingness to invest heavily in innovative cancer therapeutics. These transactions reflect a broader industry shift toward precision medicine, particularly in oncology, where targeted therapies command significant premiums. Silexion's emergence as a potentially compelling player stems from its differentiated RNAi approach to targeting one of oncology's most challenging problems, offering broader applicability across multiple KRAS mutations compared to competitors' small molecule inhibitors. The first-generation LODER™ platform has already demonstrated promising Phase 2 results, while the next-generation SIL-204 advances toward clinical trials with successful validation of systemic administration. Notable industry analysts seem to have taken notice, with Maxim Group initiating coverage with a "strong buy" recommendation in November 2024 and an updated price target of $9. As Silexion advances toward clinical trials with SIL-204 and explores expanded development strategies, several key catalysts may lie ahead and could be worth watching closely, including metastasis impact studies, advancement towards next phases of trials, data from additional indications, potential strategic partnerships, and more positioning the company uniquely in the precision oncology landscape at a time when the industry actively seeks innovative solutions for challenging cancers. Click here to Subscribe for more updates like this Read out Previous update regarding Silexion Therapeutics Read out Previous update regarding Silexion Therapeutics >> We Encourage you to read the source news from Silexion: Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models (*)Important Disclaimers & Disclosures: This report is for informational purposes only and should not be considered financial or investment advice. The author is not a registered financial or investment advisor nor does he hold any type of license or engage in any activity that would require one. The content may include forward-looking statements and opinions that may not materialize. Investors should conduct their own due diligence and consult with a qualified investment professional before making any investment decisions. This report was produced by 'PESG Research', a content brand which is part of the Wall Street Wire network, a digital coverage and news distribution subscription service and platform operated for commercial, promotional and investor relations purposes. This report contains advertising/promotional content relating to Silexion Therapeutics. Please review our detailed disclosure and disclaimer linked below which details the subscription fees the operators of PESG and the network of brands it is a part of received from Silexion Therapeutics and other customers for coverage, distribution and news promotion services, in accordance with Section 17(b) of the Securities Act. Please review the full disclaimers and disclosures this report is subject to: View source version on Contacts PESG Editorial Desk ronald@ Sign in to access your portfolio
